CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

This study tests whether CAR T-cell therapy — a treatment where a patient's own immune cells are engineered to attack cancer — is feasible and effective for people with B-cell leukemia or lymphoma that has come back or stopped responding to other treatments. **You may be eligible if...** - You have been diagnosed with relapsed or refractory B-cell leukemia (ALL) or B-cell lymphoma - Your cancer expresses CD19 (a protein found on cancer cells) - Standard treatments, including stem cell transplant, have not worked or are not an option - You are in adequate health to tolerate cell therapy **You may NOT be eligible if...** - You have active serious infections - You have significant organ dysfunction - You have received certain prior gene or cell therapies Talk to your doctor to see if this trial is right for you.